This company focuses on developing novel, best-in-class multispecific biologics intended for cancer treatment. They leverage advanced technology and deep oncology knowledge to advance antibody research and development. The goal is to create superior therapeutic candidates to improve patient outcomes in oncology.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often lack specificity, leading to systemic toxicity and limited efficacy, especially in complex tumor microenvironments. Developing targeted therapies that can effectively engage the immune system within the tumor remains a significant challenge.
Solution
92Bio is developing a pipeline of novel multispecific biologics designed to enhance cancer treatment outcomes. Their approach leverages cutting-edge antibody engineering to create therapeutics that can simultaneously target multiple cancer-related pathways. These multispecific antibodies are designed to improve the precision and effectiveness of cancer immunotherapy, potentially reducing off-target effects and improving patient outcomes by creating best-in-class molecules.
Target Audience
The primary target audience includes oncology researchers, clinicians, and pharmaceutical companies focused on developing advanced cancer immunotherapies.
Features
- Development of novel multispecific antibodies for cancer immunotherapy
- Focus on creating biologics with enhanced target specificity and reduced systemic toxicity
- Utilization of advanced antibody engineering techniques
- Strategic alliances to accelerate research and development